CO5140077A1 - STABLE INSOLUBLE COMPLEX IN WATER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHODS FOR PREPARATION. . - Google Patents
STABLE INSOLUBLE COMPLEX IN WATER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHODS FOR PREPARATION. .Info
- Publication number
- CO5140077A1 CO5140077A1 CO99059117A CO99059117A CO5140077A1 CO 5140077 A1 CO5140077 A1 CO 5140077A1 CO 99059117 A CO99059117 A CO 99059117A CO 99059117 A CO99059117 A CO 99059117A CO 5140077 A1 CO5140077 A1 CO 5140077A1
- Authority
- CO
- Colombia
- Prior art keywords
- weight
- active compound
- water insoluble
- polymer
- ionic polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Abstract
Un complejo insoluble en agua que comprende al menos 20% en peso de un polímero iónico insoluble en agua que tiene un peso molecular superior a 80.000 D (1.32 x 10-19 g) y una temperatura de transición vítrea igual o superior a 50° C, y de 0.1 a 80% en peso de un compuesto activo estable y, amorfo que tiene una solubilidad acuosa inferior a 1 mg/ml.Un método para la preparación de un complejo insoluble en agua compuesto de al menos un 20% en peso de un polímero iónico que tiene un peso molecular superior a 80.000 D (1.32 x 10-19 g) y una temperatura de transición vítrea igual o superior a 50° C y, de 0.1 a 80% en peso de un compuesto activo estable y amorfo, preparado mediante: (a) la fusión conjunta del compuesto terapéuticamente activo y el polímero iónico; y(b) enfriamiento de la mezcla resultante del paso (a).Una composición farmacéutica que comprende un complejo insoluble en agua compuesto de al menos 20% en peso de un polímero iónico insoluble en agua que tiene un peso molecular superior a 80.000 D (1.32 x 10-19 g) y una temperatura de transición vítrea igual o superior a 50° C, de 0.1 a 80% en peso de un compuesto activo que tiene una solubilidad acuosa inferior a 1 mg/ml, y un soporte.2Un método para la preparación de una composición farmacéutica que comprende un complejo insoluble en agua compuesto de al menos un 20% en peso de un polímero iónico insoluble en agua que tiene un peso molecular superior a 80.000 D (1.32 x 10-19 g) y una temperatura de transición vítrea igual o superior a 50° C y, de 0.1 a 80% en peso de un compuesto activo que tiene una solubilidad acuosa inferior a 1 mg/ml, que comprende:(a) la disolución del compuesto terapéuticamente activo y el polímero iónico en un disolvente orgánico que provee buena solubilidad para ambos el compuesto activo y el polímero;(b) la puesta en contacto de la solución del paso (a) con una solución acuosa a un pH en el cual el polímero iónico es escasamente soluble, con lo cual tiene lugar la microprecipitación del compuesto terapéuticamente activo y el polímero iónico en forma de un complejo compuesto/polímero;(c) la mezcla del complejo compuesto/polímero del paso (b) con un soporte y/o ingredientes adicionales convencionales.A water insoluble complex comprising at least 20% by weight of a water insoluble ionic polymer having a molecular weight greater than 80,000 D (1.32 x 10-19 g) and a glass transition temperature equal to or greater than 50 ° C , and from 0.1 to 80% by weight of a stable and amorphous active compound having an aqueous solubility of less than 1 mg / ml. A method for the preparation of a water insoluble complex composed of at least 20% by weight of an ionic polymer having a molecular weight greater than 80,000 D (1.32 x 10-19 g) and a glass transition temperature equal to or greater than 50 ° C and 0.1 to 80% by weight of a stable and amorphous active compound, prepared by: (a) the joint fusion of the therapeutically active compound and the ionic polymer; and (b) cooling the mixture resulting from step (a). A pharmaceutical composition comprising a water insoluble complex composed of at least 20% by weight of a water insoluble ionic polymer having a molecular weight greater than 80,000 D ( 1.32 x 10-19 g) and a glass transition temperature equal to or greater than 50 ° C, from 0.1 to 80% by weight of an active compound having an aqueous solubility of less than 1 mg / ml, and a support.2 A method for the preparation of a pharmaceutical composition comprising a water insoluble complex composed of at least 20% by weight of a water insoluble ionic polymer having a molecular weight greater than 80,000 D (1.32 x 10-19 g) and a temperature of glass transition equal to or greater than 50 ° C and, from 0.1 to 80% by weight of an active compound having an aqueous solubility of less than 1 mg / ml, comprising: (a) the solution of the therapeutically active compound and the polymer ionic in an organic solvent that pro The active compound and the polymer have good solubility for both; (b) the contacting of the solution of step (a) with an aqueous solution at a pH in which the ionic polymer is sparingly soluble, whereby the microprecipitation of the therapeutically active compound and the ionic polymer in the form of a compound / polymer complex; (c) mixing the compound / polymer complex of step (b) with a conventional additional support and / or ingredients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10133698P | 1998-09-22 | 1998-09-22 | |
US13653199P | 1999-05-28 | 1999-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5140077A1 true CO5140077A1 (en) | 2002-03-22 |
Family
ID=26798138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99059117A CO5140077A1 (en) | 1998-09-22 | 1999-09-17 | STABLE INSOLUBLE COMPLEX IN WATER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHODS FOR PREPARATION. . |
Country Status (33)
Country | Link |
---|---|
US (1) | US6350786B1 (en) |
EP (1) | EP0988863B2 (en) |
JP (5) | JP2000095708A (en) |
KR (1) | KR100362019B1 (en) |
CN (1) | CN1201821C (en) |
AR (2) | AR022096A1 (en) |
AT (1) | ATE265232T1 (en) |
AU (1) | AU770745B2 (en) |
BR (1) | BR9904283A (en) |
CA (1) | CA2282906C (en) |
CO (1) | CO5140077A1 (en) |
CZ (1) | CZ300215B6 (en) |
DE (1) | DE69916733T3 (en) |
DK (1) | DK0988863T4 (en) |
ES (1) | ES2218918T5 (en) |
HK (1) | HK1026632A1 (en) |
HR (1) | HRP990287B1 (en) |
HU (1) | HU228341B1 (en) |
ID (1) | ID24034A (en) |
IL (1) | IL131957A (en) |
MA (1) | MA26692A1 (en) |
MY (1) | MY124377A (en) |
NO (1) | NO326928B1 (en) |
NZ (1) | NZ337884A (en) |
PE (1) | PE20001049A1 (en) |
PL (1) | PL202757B1 (en) |
PT (1) | PT988863E (en) |
RS (1) | RS50193B (en) |
RU (1) | RU2240827C2 (en) |
SG (1) | SG97131A1 (en) |
SI (1) | SI0988863T2 (en) |
TR (1) | TR199902324A3 (en) |
TW (1) | TWI234465B (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2307482T3 (en) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | SOLID PHARMACEUTICAL DISPERSIONS. |
US6440959B1 (en) | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
AR033651A1 (en) * | 1999-10-01 | 2004-01-07 | Hoffmann La Roche | DERIVATIVES OF PYRIMIDINE-2,4,6-TRIONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
JP4786113B2 (en) * | 2000-05-16 | 2011-10-05 | オーソーマクニール ファーマシューティカル, インコーポレイテッド | Method for coating medical devices using supercritical carbon dioxide |
US6482847B2 (en) | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US6469179B1 (en) | 2000-10-03 | 2002-10-22 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US6716845B2 (en) | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
EP1401404B1 (en) * | 2001-05-30 | 2008-04-16 | Csir | Method of encapsulating an active substance |
US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
ATE444060T1 (en) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS |
DE60237602D1 (en) | 2001-06-22 | 2010-10-21 | Bend Res Inc | PHARMACEUTICAL COMPOSITION CONTAINING HEAVY SOLUBLE AND ACIDIC TOXIC SUBSTANCES AND NEUTRALIZED ANIONIC POLYMERS |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
CN1309370C (en) * | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
WO2004014342A1 (en) | 2002-08-12 | 2004-02-19 | Pfizer Products Inc. | Pharmaceutical compositions of semi-ordered drugs and polymers |
DE10351087A1 (en) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Solid active ingredient formulation |
JP4947482B2 (en) * | 2003-11-14 | 2012-06-06 | 味の素株式会社 | Sustained release oral administration of phenylalanine derivatives |
CN101664411A (en) | 2003-11-14 | 2010-03-10 | 味之素株式会社 | Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative |
KR100771411B1 (en) * | 2004-04-01 | 2007-10-30 | 에프. 호프만-라 로슈 아게 | Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones |
AR049915A1 (en) * | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | COMPOUNDS WITH BORO CONTENT AND METHODS OF USE OF THE SAME |
WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
CN101115469A (en) * | 2004-12-28 | 2008-01-30 | 卫材R&D管理有限公司 | Quick disintegration tablet and method of producing the same |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
KR101238525B1 (en) * | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Novel benzylamine derivatives as cetp inhibitors |
EP1690528A1 (en) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent |
EP1885338A1 (en) * | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
EP1767194A1 (en) * | 2005-06-09 | 2007-03-28 | Helm AG | Process for the preparation of adsorbates of drospirenone |
BRPI0611863B1 (en) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | COMPOUND, AS WELL AS COMPOSITION AND KIT COMPRISING THE SAME, INTERMEDIATE COMPOUND IN THE PREPARATION OF THE SAME, METHOD FOR TREATMENT AND USE OF THE SAME |
US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
BRPI0714265A2 (en) * | 2006-08-10 | 2013-04-16 | Cipla Ltd | solid oral composition, process for preparing a solid oral composition, use of a composition and method for treating HIV |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (en) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
WO2008081829A1 (en) | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | Aminoalkylmethacrylate copolymer e for maintaining solubility of poorly water-soluble drug |
CN101702878B (en) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | Pharmaceutical compositions for poorly soluble drugs |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
EP1997479A1 (en) * | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
EP2214635A1 (en) * | 2007-10-19 | 2010-08-11 | Purdue Research Foundation | Solid formulations of crystalline compounds |
US7794750B2 (en) * | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
KR20100073454A (en) * | 2008-12-23 | 2010-07-01 | 국립암센터 | Novel pyrazolodiazepine compound as an transglutaminase inhibitor, the preparation method thereof and a composition containing the same |
MY172424A (en) * | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
BR112012012156A2 (en) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compounds and methods for kinase modulation, and indications for this |
KR20130126451A (en) * | 2010-05-31 | 2013-11-20 | 아스테라스 세이야쿠 가부시키가이샤 | Solid dispersion comprising triazole compound |
TR201816421T4 (en) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Compounds and methods for kinase modulation and their indications. |
CN103391769A (en) | 2011-02-17 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
CN108498465B (en) * | 2011-10-14 | 2022-05-17 | 阵列生物制药公司 | Solid dispersions of an ErbB2(HER2) inhibitor |
SI2827900T1 (en) | 2012-03-23 | 2018-06-29 | Array Biopharma, Inc. | Amorphous solid dispersion for use in the treatment of brain cancer |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JO3339B1 (en) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
RU2015123632A (en) | 2012-11-19 | 2017-01-10 | Др. Редди'С Лабораторис Лтд. | PHARMACEUTICAL COMPOSITIONS OF CETR INHIBITORS |
CN105007899A (en) * | 2012-12-20 | 2015-10-28 | 卡希夫制药有限责任公司 | Orally disintegrating tablet formulation for enhanced bioavailability |
MY192032A (en) | 2013-01-22 | 2022-07-24 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
TWI615157B (en) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | Solid dispersion comprising amorphous cilostazol |
US20160213575A1 (en) * | 2013-09-11 | 2016-07-28 | 3M Innovative Properties Company | Coating compositions, dental structures thereof and methods for generating contrast |
US20160303102A1 (en) * | 2013-12-05 | 2016-10-20 | Alrise Biosystems Gmbh | Process for the production of drug formulations for oral administration |
PT107846B (en) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Production of Amorphous Solid Dispersion Nanoparticles by Controlled Co-Precipitation |
BR112017025739A2 (en) * | 2015-05-29 | 2018-08-07 | Sun Pharmaceutical Ind Ltd | isotretinoin oral pharmaceutical composition having increased bioavailability, process for preparing it and method of treatment |
EP3447056A4 (en) | 2016-12-13 | 2019-09-18 | Nanjing Transthera Biosciences Co. Ltd. | Multi-kinase inhibitor compound, and crystal form and use thereof |
KR20200014298A (en) | 2017-04-28 | 2020-02-10 | 시애틀 지네틱스, 인크. | Treatment of HER2-positive cancer |
KR102082775B1 (en) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | Formulation with enhanced water solubility and bioavailability |
RU2725879C2 (en) * | 2018-07-26 | 2020-07-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Interpolymer carrier for oral systems of controlled delivery of active pharmaceutical ingredients |
JP2022509965A (en) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R, 3S) -6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl) -1,2,2-trimethylpiperazine and 4-((1R, 3S)- Prodrug of 6-chloro-3- (phenyl-d5) -2,3-dihydro-1H-indene-1-yl) -2,2-dimethyl-1- (methyl-d3) piperazine |
EP4093379A1 (en) | 2020-01-24 | 2022-11-30 | Nanocopoeia LLC | Amorphous solid dispersions of dasatinib and uses thereof |
IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
KR20220129628A (en) | 2020-03-03 | 2022-09-23 | 데쿠세리아루즈 가부시키가이샤 | Method for manufacturing an image display device |
EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
FI864812A (en) * | 1985-11-27 | 1987-05-28 | Syntex Inc | FOERFARANDE FOER FRAMSTAELLNING AV AMORFA BENSIMIDAZOLDERIVAT. |
CZ280738B6 (en) * | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituted pyrroles, their use for preparing medicaments and medicaments based thereon |
JP2528706B2 (en) † | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | Pharmaceutical composition of dihydropyridine compound |
USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH0729926B2 (en) † | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | Composition for easily absorbable preparations |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU1537292A (en) † | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
GB9511220D0 (en) † | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
ATE240734T1 (en) * | 1995-07-26 | 2003-06-15 | Kyowa Hakko Kogyo Kk | PREPARATION OF XANTHINDERIVATES AS A SOLID DISPERSION |
AU7106996A (en) † | 1995-09-07 | 1997-03-27 | Fuisz Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
DE19548624A1 (en) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | New barbituric acid derivatives, processes for their preparation and medicaments containing these compounds |
JPH09208459A (en) * | 1996-02-07 | 1997-08-12 | Eisai Co Ltd | Preparation improved in solubility |
JP3737518B2 (en) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー, エル.ピー. | Water-soluble paclitaxel prodrug |
JP2000514057A (en) * | 1996-06-28 | 2000-10-24 | シェーリング コーポレイション | Solid solution of antifungal agent with enhanced bioavailability |
PE91598A1 (en) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
CZ299068B6 (en) | 1998-03-17 | 2008-04-16 | F. Hoffmann-La Roche Ag | Substituted bisindolylmaleimide and pharmaceutical composition containing thereof |
-
1999
- 1999-09-07 US US09/391,060 patent/US6350786B1/en not_active Expired - Lifetime
- 1999-09-13 AT AT99117908T patent/ATE265232T1/en active
- 1999-09-13 DE DE69916733T patent/DE69916733T3/en not_active Expired - Lifetime
- 1999-09-13 SI SI9930573T patent/SI0988863T2/en unknown
- 1999-09-13 ES ES99117908T patent/ES2218918T5/en not_active Expired - Lifetime
- 1999-09-13 DK DK99117908T patent/DK0988863T4/en active
- 1999-09-13 PT PT99117908T patent/PT988863E/en unknown
- 1999-09-13 EP EP99117908A patent/EP0988863B2/en not_active Expired - Lifetime
- 1999-09-16 IL IL13195799A patent/IL131957A/en not_active IP Right Cessation
- 1999-09-17 NZ NZ337884A patent/NZ337884A/en not_active IP Right Cessation
- 1999-09-17 PE PE1999000947A patent/PE20001049A1/en not_active IP Right Cessation
- 1999-09-17 SG SG9904570A patent/SG97131A1/en unknown
- 1999-09-17 CZ CZ0330499A patent/CZ300215B6/en not_active IP Right Cessation
- 1999-09-17 CO CO99059117A patent/CO5140077A1/en unknown
- 1999-09-20 AU AU48807/99A patent/AU770745B2/en not_active Expired
- 1999-09-20 ID IDP990878D patent/ID24034A/en unknown
- 1999-09-20 HR HR990287 patent/HRP990287B1/en not_active IP Right Cessation
- 1999-09-20 CA CA2282906A patent/CA2282906C/en not_active Expired - Lifetime
- 1999-09-20 TW TW088116184A patent/TWI234465B/en not_active IP Right Cessation
- 1999-09-20 HU HU9903189A patent/HU228341B1/en unknown
- 1999-09-20 MY MYPI99004065A patent/MY124377A/en unknown
- 1999-09-20 AR ARP990104725A patent/AR022096A1/en not_active Application Discontinuation
- 1999-09-21 MA MA25778A patent/MA26692A1/en unknown
- 1999-09-21 JP JP11267142A patent/JP2000095708A/en not_active Withdrawn
- 1999-09-21 NO NO19994583A patent/NO326928B1/en not_active IP Right Cessation
- 1999-09-21 RU RU99120377/15A patent/RU2240827C2/en active
- 1999-09-21 RS YUP-473/99A patent/RS50193B/en unknown
- 1999-09-21 TR TR1999/02324A patent/TR199902324A3/en unknown
- 1999-09-21 CN CNB991194063A patent/CN1201821C/en not_active Expired - Lifetime
- 1999-09-21 BR BR9904283-5A patent/BR9904283A/en not_active Application Discontinuation
- 1999-09-22 PL PL335592A patent/PL202757B1/en unknown
- 1999-09-22 KR KR1019990041130A patent/KR100362019B1/en active IP Right Grant
-
2000
- 2000-09-19 HK HK00105891A patent/HK1026632A1/en not_active IP Right Cessation
-
2007
- 2007-06-06 JP JP2007150911A patent/JP2007224048A/en active Pending
-
2011
- 2011-04-13 AR ARP110101253A patent/AR080892A2/en not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230446A patent/JP6253135B2/en not_active Expired - Lifetime
-
2015
- 2015-07-16 JP JP2015141952A patent/JP2015187170A/en active Pending
-
2016
- 2016-08-31 JP JP2016169245A patent/JP6534979B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5140077A1 (en) | STABLE INSOLUBLE COMPLEX IN WATER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHODS FOR PREPARATION. . | |
UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
CY1120513T1 (en) | HIGH CONCENTRATION MINOXIDIL COMPOSITION | |
BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
BR0014486A (en) | Pharmaceutical compositions containing stabilized liquid polypeptide | |
CY1112527T1 (en) | COMPOSITIONS CONTAINING AMIODARONE AND SULFOALKYL ETHER CYCLODEXTRIN | |
EA200400432A1 (en) | UREA DERIVATIVES | |
BR9913433A (en) | Stabilized disinfectant system composed of two parts and related compositions and methods | |
BR9906735A (en) | Aqueous liquid pharmaceutical composition | |
BR9916980A (en) | Substituted bicyclic derivatives useful as anti-cancer agents | |
HU229184B1 (en) | Highly concentrated stable meloxicam solutions | |
BRPI0611170A2 (en) | injectable compositions and process for preparing such compositions | |
ATE468126T1 (en) | GINGER EXTRACT PREPARATION | |
ES2178268T3 (en) | CONTROLLED RELEASE FORMULATIONS. | |
RU2006105645A (en) | LIOPHILIZED COMPOSITIONS CCI-779 | |
ES2108129T3 (en) | NEW DERIVATIVES OF PIRAZINE, ITS PREPARATION AND USE. | |
TR200401436T4 (en) | Pharmaceutical composition containing pemetrexed with monothioglycerol, L-system or thioglycolic acid | |
BG64664B1 (en) | Nimesulide gel systems for local administration | |
EA200200489A1 (en) | NEW COMPOUNDS OF BENZOTHIADIAZINE, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
KR20100132557A (en) | Stabilization method of eye drops containing latanoprost as the active ingredient | |
RU2000119750A (en) | NEW PENTACCHARIDES, METHODS OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
JPS6416724A (en) | Stable and injectable vinca dimer salt solution | |
CA2116192A1 (en) | Highly concentrated tcf pharmaceutical preparations | |
BR9914441A (en) | High purity composition comprising (7-alpha, 17-alpha) - 17-hydroxy-7-methyl-19-nor-17-pregn- 5 (10) -en-20-in-3-one, process for preparing the high purity compositions, and pharmaceutical dosage unit | |
MX9400176A (en) | METHOD AND COMPOSITION TO INHIBIT THE CORROSION OF METALS USING POLITARTARIC ACIDS. |